{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T11:55:54Z","timestamp":1772538954523,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2008,7,22]],"date-time":"2008-07-22T00:00:00Z","timestamp":1216684800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s00228-008-0525-3","type":"journal-article","created":{"date-parts":[[2008,7,21]],"date-time":"2008-07-21T09:07:07Z","timestamp":1216631227000},"page":"1163-1173","source":"Crossref","is-referenced-by-count":57,"title":["CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction"],"prefix":"10.1007","volume":"64","author":[{"given":"Ksenia","family":"Goryachkina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Burbello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Boldueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Babak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif","family":"Bertilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,7,22]]},"reference":[{"key":"525_CR1","unstructured":"WHOSTAT (2005)"},{"issue":"9","key":"525_CR2","first-page":"e82","volume":"110","author":"EM Antman","year":"2004","unstructured":"Antman EM, Anbe DT, Armstrong PW et al (2004) ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110(9):e82\u2013e292","journal-title":"Circulation"},{"issue":"12","key":"525_CR3","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/00019501-199312000-00007","volume":"4","author":"J Herlitz","year":"1993","unstructured":"Herlitz J, Karlson BW, Hjalmarson A (1993) Ten-year mortality rate after development of acute myocardial infarction in relation to clinical history and observations during hospital stay: experience from the Goteborg metoprolol trial. Coron Artery Dis 4(12):1077\u20131083","journal-title":"Coron Artery Dis"},{"issue":"25","key":"525_CR4","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1056\/NEJM198212163072505","volume":"307","author":"MS Lennard","year":"1982","unstructured":"Lennard MS, Silas JH, Freestone S et al (1982) Oxidation phenotype\u2013a major determinant of metoprolol metabolism and response. N Engl J Med 307(25):1558\u20131560","journal-title":"N Engl J Med"},{"issue":"5","key":"525_CR5","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/sj.clpt.6100358","volume":"82","author":"L Bertilsson","year":"2007","unstructured":"Bertilsson L (2007) Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects. Clin Pharmacol Ther 82(5):606\u2013609","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"525_CR6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00228-007-0404-3","volume":"64","author":"K Goryachkina","year":"2008","unstructured":"Goryachkina K, Burbello A, Boldueva S et al (2008) Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol 64(3):275\u2013282","journal-title":"Eur J Clin Pharmacol"},{"issue":"5\u20136","key":"525_CR7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1050-3862(98)00019-9","volume":"14","author":"KJ Livak","year":"1999","unstructured":"Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 14(5\u20136):143\u2013149","journal-title":"Genet Anal"},{"issue":"1","key":"525_CR8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/clinchem\/46.1.18","volume":"46","author":"M Garcia-Barcelo","year":"2000","unstructured":"Garcia-Barcelo M, Chow LY, Chiu HF et al (2000) Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem 46(1):18\u201323","journal-title":"Clin Chem"},{"issue":"2","key":"525_CR9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0378-1119(98)00567-8","volume":"226","author":"E Lundqvist","year":"1999","unstructured":"Lundqvist E, Johansson I, Ingelman-Sundberg M (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226(2):327\u2013338","journal-title":"Gene"},{"issue":"2","key":"525_CR10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/14622416.3.2.229","volume":"3","author":"LD Bradford","year":"2002","unstructured":"Bradford LD (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3(2):229\u2013243","journal-title":"Pharmacogenomics"},{"issue":"4","key":"525_CR11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00228-003-0606-2","volume":"59","author":"EA Gaikovitch","year":"2003","unstructured":"Gaikovitch EA, Cascorbi I, Mrozikiewicz PM et al (2003) Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 59(4):303\u2013312","journal-title":"Eur J Clin Pharmacol"},{"key":"525_CR12","doi-asserted-by":"crossref","unstructured":"Opie L (2005) Drugs for the heart 6th edition","DOI":"10.1111\/j.1540-8191.2006.00211.x"},{"key":"525_CR13","unstructured":"Astra Zeneca FDA report NDA 19\u2013962\/S-027. 2005 [cited January, 2008]; Available from: http:\/\/redpoll.pharmacy.ualberta.ca\/drugbank\/drugBank\/FDA_labels\/019962.pdf ."},{"issue":"9 Pt 2","key":"525_CR14","doi-asserted-by":"crossref","first-page":"291S","DOI":"10.1016\/S0895-7061(01)02174-4","volume":"14","author":"WJ Elliot","year":"2001","unstructured":"Elliot WJ (2001) Cyclic and circadian variations in cardiovascular events. Am J Hypertens 14(9 Pt 2):291S\u2013295S","journal-title":"Am J Hypertens"},{"issue":"6","key":"525_CR15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00008571-200208000-00007","volume":"12","author":"T Rau","year":"2002","unstructured":"Rau T, Heide R, Bergmann K et al (2002) Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 12(6):465\u2013472","journal-title":"Pharmacogenetics"},{"issue":"1","key":"525_CR16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2710.2006.00699.x","volume":"31","author":"R Ismail","year":"2006","unstructured":"Ismail R, Teh LK (2006) The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther 31(1):99\u2013109","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"525_CR17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","volume":"53","author":"L Bertilsson","year":"2002","unstructured":"Bertilsson L, Dahl ML, Dalen P et al (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53(2):111\u2013122","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"525_CR18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s002280050495","volume":"54","author":"R Koytchev","year":"1998","unstructured":"Koytchev R, Alken RG, Vlahov V et al (1998) Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol. Eur J Clin Pharmacol 54(6):469\u2013474","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"525_CR19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2165\/00003088-198005060-00004","volume":"5","author":"CG Regardh","year":"1980","unstructured":"Regardh CG, Johnsson G (1980) Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet 5(6):557\u2013569","journal-title":"Clin Pharmacokinet"},{"issue":"7A","key":"525_CR20","doi-asserted-by":"crossref","first-page":"39L","DOI":"10.1016\/j.amjcard.2006.07.018","volume":"98","author":"M Packer","year":"2006","unstructured":"Packer M, Lukas MA, Tenero DM et al (2006) Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Am J Cardiol 98(7A):39L\u201345L","journal-title":"Am J Cardiol"},{"issue":"5","key":"525_CR21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clpt.2006.08.004","volume":"80","author":"PA Thurmann","year":"2006","unstructured":"Thurmann PA, Haack S, Werner U et al (2006) Tolerability of beta-blockers metabolized via cytochrome P450 2D6 is sex-dependent. Clin Pharmacol Ther 80(5):551\u2013553","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"525_CR22","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1053\/cp.1999.v66.103400001","volume":"66","author":"AB Luzier","year":"1999","unstructured":"Luzier AB, Killian A, Wilton JH et al (1999) Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 66(6):594\u2013601","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"525_CR23","first-page":"1403","volume":"161","author":"PA Rochon","year":"1999","unstructured":"Rochon PA, Anderson GM, Tu JV et al (1999) Use of beta-blocker therapy in older patients after acute myocardial infarction in Ontario. CMAJ 161(11):1403\u20131408","journal-title":"CMAJ"},{"issue":"1","key":"525_CR24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/oxfordjournals.eurheartj.a060043","volume":"13","author":"G Olsson","year":"1992","unstructured":"Olsson G, Wikstrand J, Warnold I et al (1992) Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J 13(1):28\u201332","journal-title":"Eur Heart J"},{"issue":"7","key":"525_CR25","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1532-5415.1995.tb07044.x","volume":"43","author":"KC Park","year":"1995","unstructured":"Park KC, Forman DE, Wei JY (1995) Utility of beta-blockade treatment for older postinfarction patients. J Am Geriatr Soc 43(7):751\u2013755","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"525_CR26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.0954-6820.1985.tb02698.x","volume":"217","author":"J Herlitz","year":"1985","unstructured":"Herlitz J, Hjalmarson A, Holmberg S et al (1985) Tolerability to treatment with metoprolol in acute myocardial infarction in relation to age. Acta Med Scand 217(3):293\u2013298","journal-title":"Acta Med Scand"},{"issue":"2","key":"525_CR27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00613821","volume":"24","author":"CG Regardh","year":"1983","unstructured":"Regardh CG, Landahl S, Larsson M et al (1983) Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals. Eur J Clin Pharmacol 24(2):221\u2013226","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"525_CR28","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/BF00278584","volume":"38","author":"ES Dimenas","year":"1990","unstructured":"Dimenas ES, Dahlof CG, Heibel B et al (1990) Subjective symptoms and pharmacokinetics\/dynamics of metoprolol CR in elderly subjects\u2014a comparison with atenolol. Eur J Clin Pharmacol 38(6):571\u2013578","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"525_CR29","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2165\/00003495-200565060-00006","volume":"65","author":"KE Ellison","year":"2005","unstructured":"Ellison KE, Gandhi G (2005) Optimising the use of beta-adrenoceptor antagonists in coronary artery disease. Drugs 65(6):787\u2013797","journal-title":"Drugs"},{"issue":"1","key":"525_CR30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0002-9149(83)90072-3","volume":"52","author":"CM Pratt","year":"1983","unstructured":"Pratt CM, Yepsen SC, Bloom MG et al (1983) Evaluation of metoprolol in suppressing complex ventricular arrhythmias. Am J Cardiol 52(1):73\u201378","journal-title":"Am J Cardiol"},{"issue":"10","key":"525_CR31","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1161\/CIRCULATIONAHA.106.178233","volume":"114","author":"DP Zipes","year":"2006","unstructured":"Zipes DP, Camm AJ, Borggrefe M et al (2006) ACC\/AHA\/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology\/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114(10):e385\u2013e484","journal-title":"Circulation"},{"issue":"11","key":"525_CR32","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/01.CIR.0000141575.92958.9C","volume":"110","author":"M Frossard","year":"2004","unstructured":"Frossard M, Fuchs I, Leitner JM et al (2004) Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110(11):1392\u20131397","journal-title":"Circulation"},{"issue":"4","key":"525_CR33","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0006-3223(96)00345-9","volume":"42","author":"F Laghrissi-Thode","year":"1997","unstructured":"Laghrissi-Thode F, Wagner WR, Pollock BG et al (1997) Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 42(4):290\u2013295","journal-title":"Biol Psychiatry"},{"issue":"2","key":"525_CR34","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.pharmthera.2005.05.011","volume":"112","author":"RH Elbekai","year":"2006","unstructured":"Elbekai RH, El-Kadi AO (2006) Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther 112(2):564\u2013587","journal-title":"Pharmacol Ther"},{"issue":"6","key":"525_CR35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00008571-200306000-00002","volume":"13","author":"AM Yu","year":"2003","unstructured":"Yu AM, Idle JR, Herraiz T et al (2003) Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13(6):307\u2013319","journal-title":"Pharmacogenetics"},{"issue":"8637","key":"525_CR36","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(89)90094-9","volume":"1","author":"L Bertilsson","year":"1989","unstructured":"Bertilsson L, Alm C, De Las Carreras C et al (1989) Debrisoquine hydroxylation polymorphism and personality. Lancet 1(8637):555","journal-title":"Lancet"},{"issue":"1","key":"525_CR37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0447.1993.tb03325.x","volume":"87","author":"A Llerena","year":"1993","unstructured":"Llerena A, Edman G, Cobaleda J et al (1993) Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 87(1):23\u201328","journal-title":"Acta Psychiatr Scand"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-008-0525-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-008-0525-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-008-0525-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T04:25:35Z","timestamp":1588825535000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-008-0525-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,22]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["525"],"URL":"https:\/\/doi.org\/10.1007\/s00228-008-0525-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,22]]}}}